The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
"The FDA's approval of Imdelltra marks a pivotal moment for patients battling [extensive-stage small cell lung cancer]," Dr.
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small ... antibody to gain FDA approval in cancer, and the first in small ...
Results from a mid-stage trial , opens new tab ... drugs. Amgen said it will need to complete its larger, pivotal trial in advanced small cell lung cancer to receive full FDA approval of the ...
"It's just one of the most dreadful cancers and so we needed a new solution," he said. Amgen's drug is called a bispecific T-cell engager, which is designed to redirect the immune system's T-cells ...
"The FDA's approval of ... chief scientific officer at drug maker Amgen, said in a company news release. "Imdelltra offers these patients who are in urgent need of new innovative therapies hope ...
The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...